Six weeks on Mounjaro: what's actually happening by now

The titration decision your prescriber is weighing right now

Mounjaro's licensed schedule starts at 2.5 mg. That dose exists to let your gut adjust, not to deliver the full therapeutic effect. A typical first pen covers four weekly injections at 2.5 mg. By week five or six, the question on the table is whether to step up to 5 mg or to stay put a little longer. That call sits entirely with your prescriber, who will look at how you've tolerated the starter dose, whether GI symptoms have settled, and any relevant changes in your weight or health picture.

For a fuller picture of what the first four weeks look like before this point, the week-four summary covers the early phase in detail. The step-up to 5 mg is not automatic, some people benefit from an extra few weeks at the lower level, and there is nothing wrong with that. Pushing the pace on titration when side effects haven't cleared tends to make things harder, not faster.

Tirzepatide (the active ingredient in Mounjaro) is a dual GIP and GLP-1 receptor agonist, the only weight-management medicine in the UK that activates both pathways simultaneously. The tirzepatide overview explains how those two mechanisms work together if you want the pharmacology. At six weeks, what matters practically is that the dose you're on is building a cumulative effect, and the prescriber's job is to move you through the schedule at a pace your body can handle.

What your body is likely doing at this stage

Appetite suppression tends to become more predictable between weeks four and eight than it was at the start. The early weeks can feel uneven, some days the food noise quietens noticeably, others less so. By six weeks, many people describe a more consistent background reduction in hunger, particularly between meals. That doesn't mean every day is the same, but the pattern is usually clearer.

GI effects (nausea, loose stools, reflux, and occasionally constipation) are most pronounced in the first few weeks and after dose increases, according to the NHS tirzepatide medicines page. By week six on a stable dose, these tend to have eased for most people. If you've just stepped up to 5 mg, a fresh wave of mild GI symptoms in the first week or two of the new dose is common and usually short-lived. Staying well hydrated and eating smaller portions slowly both help; your prescriber or the patient information leaflet in the box can give you specific advice.

Fatigue and headaches are reported by some people, especially in the opening weeks. These too typically improve as the body settles. If anything feels severe or persistent (particularly severe stomach pain that radiates to the back) that warrants prompt medical attention. The MHRA highlighted acute pancreatitis as a known, infrequent but serious risk for GLP-1 medicines in a Drug Safety Update issued in January 2026; it's not common, but it's the symptom pattern to take seriously rather than wait out.

How much weight loss is realistic after six weeks?

This is probably the question that weighs most on people's minds at this point, and the honest answer is: variable, and not yet the full picture. The large SURMOUNT-1 trial, which ran for 72 weeks, reported an average body-weight reduction of around 20–21% at the highest dose. Six weeks is a small fraction of that timeline. Early results also depend heavily on which dose you're on: someone still on 2.5 mg will typically see less change than someone already at 5 mg, because the appetite effect is dose-related.

Some people lose several kilograms by week six; others lose less and feel frustrated. Both can be entirely on track. The Mounjaro treatment page sets out the full evidence picture if you want to understand the longer arc. What the six-week mark is really good for is confirming that you're tolerating treatment, that the clinical picture supports continuing, and whether the dose step-up is the right next move, not for judging the final result. If you're curious how things compare further along, the eight-week experience covers what typically follows this point.

What if things aren't going to plan?

If you're six weeks in and side effects haven't improved, weight hasn't shifted at all, or you have new symptoms that concern you, the right move is to contact whoever manages your treatment. At nume, aftercare is available seven days a week, you don't have to wait for a scheduled review appointment. Persistent nausea severe enough to stop you eating normally, dehydration from GI illness, or any sign of an allergic reaction all need the same-day attention your GP or 111 can provide.

Some people at this stage consider stopping. A temporary break has implications, the guide to stopping Mounjaro covers what typically happens and what a prescriber will want to discuss before that decision is made. It's also worth reading if you've missed doses and aren't sure whether to resume at the same level or restart.

If you're not yet on treatment but trying to understand what a typical course looks like before committing, the consultation page is the starting point. There's no cost to the clinical assessment, and a prescriber will review your suitability the same day. For context on how private treatment is priced, the Mounjaro cost guide gives an honest breakdown of what the market looks like and what a single transparent price actually covers. Check your eligibility whenever you're ready.